logo
Plus   Neg
Share
Email

FATE Catches Eyes, LJPC Upbeat, CLSD To Submit XIPERE NDA By Year-end

pharmaup-oct25-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Fate Therapeutics Inc. (FATE)

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders.

Gained 17.68% to close Thursday's (Oct.25) trading at $13.51.

News: No news

Clinical Trials:

-- FATE-NK100, under phase I study, for refractory / relapsed acute myeloid leukemia, dubbed VOYAGE.
-- FATE-NK100, under phase I study, for recurrent ovarian cancer, dubbed APOLLO.
-- FATE-NK100, under phase I study, for advanced solid tumors, dubbed DIMENSION.
-- ProTmune, for the prevention of graft-versus-host disease, under a phase II clinical trial, dubbed PROTECT.

2. Pulse Biosciences Inc. (PLSE)

Pulse Biosciences is a clinical stage electroceutical company pursuing multiple clinical applications of its proprietary Nano-Pulse Stimulation.

Gained 17.62% to close Thursday's trading at $10.68.

News: No news

Clinical Trials & Near-term Catalysts:

-- A multicenter study evaluating the safety and efficacy of Nano-Pulse Stimulation technology for eliminating Sebaceous Hyperplasia, an unsightly benign skin lesion that typically appears on facial skin, is underway. Data collection and analysis is on schedule to be completed during the fourth quarter of 2018.
-- A clinical study evaluating Nano-Pulse Stimulation in a common skin cancer, Basal Cell Carcinoma (BCC), is also ongoing. Study completion is slated for year-end 2018 with data to be reported during the first quarter of 2019.
-- A clinical feasibility study of Nano-Pulse Stimulation platform to treat patients with cutaneous warts was initiated as recently as this month.

3. Imprimis Pharmaceuticals Inc. (IMMY)

Gained 16.25% to close Thursday's trading at $4.22.

News: No news

You can find more about IMMY in our "In the Spotlight" column.

4. La Jolla Pharmaceutical Company (LJPC)

Gained 15.96% to close Thursday's trading at $17.66.

News: The Company reported financial results for the three and nine months ended September 30, 2018.

Net loss for the recent third quarter was $50.7 million or $1.93 per share on net product sales of $3.5 million. This compared with a net loss of $26.3 million or $1.19 per share on nil product sales in the year-ago quarter.

5. Clearside Biomedical Inc. (CLSD)

Clearside Biomedical is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases.

Gained 14.68% to close Thursday's trading at $5.78.

News: The Company announced the appointment of Thomas A. Ciulla to the position of Chief Medical Officer.

Prior to joining Clearside, Ciulla served as Vice President, Ophthalmic Strategy Lead at Spark Therapeutics Inc. (ONCE), where he defined and led medical strategy to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease.

Pipeline:

The Company's lead product candidate is XIPERE (formerly "suprachoroidal CLS-TA"), under phase III trial in patients with macular edema associated with non-infectious uveits, dubbed PEACHTREE. Top line results from this study were reported on March 5, 2018, which sent the stock up as much as 69% that day.

Near-term Catalysts:

-- The Company will highlight positive data from PEACHTREE at the upcoming American Academy of Ophthalmology 2018 Annual Meeting being held October 27-30 in Chicago, Illinois.
-- Submit an NDA for XIPERE to treat macular edema associated with non-infectious uveitis to the FDA by the end of 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>